The use of patient-derived primary cell cultures in cancer preclinical assays, including drug screens and genotoxic studies, has increased in recent years. However, their translational value is constrained by several limitations, including variability that can be caused by the culture conditions.

A battery of in vitro genotoxicity assays is currently used to detect agents with DNA damaging and carcinogenic potential. Although the sensitivity of this battery of genotoxicity assays is high, the specificity is low (“false positive hit”), especially with the mammalian cell-based assay, compared

The Vectra® Polaris™ Automated Quantitative Pathology Imaging System integrates both multispectral imaging and automated slide scanning to better visualize, analyze, quantify, and phenotype immune cells in situ in FFPE tissue sections and TMAs.